Thus, PAH patients with higher resistin levels in the overall cohort had diminished functional capacity (NYHA FC III/IV vs. I/II, P = 0.014) and increased REVEAL Registry 2.0 risk score (P = 0.0001) that may contribute to the high mortality rate (23.1% vs. 13.4%, P = 0.0001). This evidence concerns the gene RETN and pulmonary arterial hypertension.